LLY

1,074.51

-2.76%↓

JNJ

205.88

-0.89%↓

ABBV

227.29

-0.11%↓

UNH

330.19

+0.15%↑

AZN

92.73

-0.69%↓

LLY

1,074.51

-2.76%↓

JNJ

205.88

-0.89%↓

ABBV

227.29

-0.11%↓

UNH

330.19

+0.15%↑

AZN

92.73

-0.69%↓

LLY

1,074.51

-2.76%↓

JNJ

205.88

-0.89%↓

ABBV

227.29

-0.11%↓

UNH

330.19

+0.15%↑

AZN

92.73

-0.69%↓

LLY

1,074.51

-2.76%↓

JNJ

205.88

-0.89%↓

ABBV

227.29

-0.11%↓

UNH

330.19

+0.15%↑

AZN

92.73

-0.69%↓

LLY

1,074.51

-2.76%↓

JNJ

205.88

-0.89%↓

ABBV

227.29

-0.11%↓

UNH

330.19

+0.15%↑

AZN

92.73

-0.69%↓

Search

VistaGen Therapeutics Inc

Abrir

4.83 5.92

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.5600000000000005

Máximo

4.5600000000000005

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+205.54% upside

VistaGen Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de nov. de 2025, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 de nov. de 2025, 15:32 UTC

Aquisições, Fusões, Aquisições de Empresas

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 de nov. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 de nov. de 2025, 23:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de nov. de 2025, 16:05 UTC

Conversa de Mercado

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 de nov. de 2025, 16:04 UTC

Conversa de Mercado

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 de nov. de 2025, 15:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 de nov. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 de nov. de 2025, 15:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 de nov. de 2025, 15:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 de nov. de 2025, 15:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 de nov. de 2025, 15:11 UTC

Conversa de Mercado

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 de nov. de 2025, 14:26 UTC

Conversa de Mercado

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 de nov. de 2025, 14:11 UTC

Conversa de Mercado

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 de nov. de 2025, 14:11 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de nov. de 2025, 13:35 UTC

Conversa de Mercado

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 de nov. de 2025, 13:33 UTC

Conversa de Mercado

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 de nov. de 2025, 13:22 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de nov. de 2025, 13:22 UTC

Conversa de Mercado

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 de nov. de 2025, 13:17 UTC

Conversa de Mercado

LVMH Should Be Able to Recover Next Year -- Market Talk

27 de nov. de 2025, 11:13 UTC

Conversa de Mercado

European Gas Prices Come Under Pressure -- Market Talk

27 de nov. de 2025, 11:07 UTC

Ganhos

Genting: Positive About Prospects Over Longer Term

27 de nov. de 2025, 11:06 UTC

Ganhos

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: International Travel Demand Expected to Remain Resilient

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: Global Growth Expected to Remain Subdued

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 de nov. de 2025, 10:59 UTC

Ganhos

Genting Bhd 3Q Net Profit Fell 86% on Year

27 de nov. de 2025, 10:58 UTC

Ganhos

Genting Bhd 3Q Rev Rose 14% on Year

27 de nov. de 2025, 10:56 UTC

Ganhos

Genting Bhd 3Q Net MYR30.3M

27 de nov. de 2025, 10:56 UTC

Ganhos

Genting Bhd 3Q EPS MYR0.0079

Comparação entre Pares

Variação de preço

VistaGen Therapeutics Inc Previsão

Preço-alvo

By TipRanks

205.54% parte superior

Previsão para 12 meses

Média 14.33 USD  205.54%

Máximo 19 USD

Mínimo 12 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para VistaGen Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Informação Financeira

$

help-icon Live chat